Publications

Found 145 results
Filters: First Letter Of Last Name is T  [Clear All Filters]
2018
Teater M, Dominguez PM, Redmond D, Chen Z, Ennishi D, Scott DW, Cimmino L, Ghione P, Chaudhuri J, Gascoyne RD et al..  2018.  AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis.. Nat Commun. 9(1):222.
Verma N, Pan H, Doré LC, Shukla A, Li QV, Pelham-Webb B, Teijeiro V, González F, Krivtsov A, Chang C-J et al..  2018.  Author Correction: TET proteins safeguard bivalent promoters from de novo methylation in human embryonic stem cells.. Nat Genet. 50(5):764.
Sailer V, Schiffman MH, Kossai M, Cyrta J, Beg S, Sullivan B, Pua BB, Lee KSteve, Talenfeld AD, Nanus DM et al..  2018.  Bone biopsy protocol for advanced prostate cancer in the era of precision medicine.. Cancer. 124(5):1008-1015.
Sailer V, Schiffman MH, Kossai M, Cyrta J, Beg S, Sullivan B, Pua BB, Lee KSteve, Talenfeld AD, Nanus DM et al..  2018.  Bone biopsy protocol for advanced prostate cancer in the era of precision medicine.. Cancer. 124(5):1008-1015.
Bakhoum SF, Ngo B, Laughney AM, Cavallo J-A, Murphy CJ, Ly P, Shah P, Sriram RK, Watkins TBK, Taunk NK et al..  2018.  Chromosomal instability drives metastasis through a cytosolic DNA response.. Nature. 553(7689):467-472.
Liu H, Murphy CJ, Karreth FA, Emdal KB, White FM, Elemento O, Toker A, Wulf GM, Cantley LC.  2018.  Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer.. Cancer Discov. 8(3):354-369.
Markowitz GJ, Havel LS, Crowley MJp, Ban Y, Lee SB, Thalappillil JS, Narula N, Bhinder B, Elemento O, Wong STc et al..  2018.  Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival.. JCI Insight. 3(13)
Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, Hess J, Sigouros M, Donoghue A, Kossai M et al..  2018.  Patient derived organoids to model rare prostate cancer phenotypes.. Nat Commun. 9(1):2404.
Verma N, Pan H, Doré LC, Shukla A, Li QV, Pelham-Webb B, Teijeiro V, González F, Krivtsov A, Chang C-J et al..  2018.  Publisher Correction: TET proteins safeguard bivalent promoters from de novo methylation in human embryonic stem cells.. Nat Genet. 50(5):764.
Circosta P, Elia ARita, Landra I, Machiorlatti R, Todaro M, Aliberti S, Brusa D, Deaglio S, Chiaretti S, Bruna R et al..  2018.  Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms.. Oncoimmunology. 7(4):e1341032.
Verma N, Pan H, Doré LC, Shukla A, Li QV, Pelham-Webb B, Teijeiro V, González F, Krivtsov A, Chang C-J et al..  2018.  TET proteins safeguard bivalent promoters from de novo methylation in human embryonic stem cells.. Nat Genet. 50(1):83-95.
Dominguez PM, Ghamlouch H, Rosikiewicz W, Kumar P, Béguelin W, Fontán L, Rivas MA, Pawlikowska P, Armand M, Mouly E et al..  2018.  TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis.. Cancer Discov. 8(12):1632-1653.
Dominguez PM, Ghamlouch H, Rosikiewicz W, Kumar P, Béguelin W, Fontán L, Rivas MA, Pawlikowska P, Armand M, Mouly E et al..  2018.  TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis.. Cancer Discov. 8(12):1632-1653.
Dominguez PM, Ghamlouch H, Rosikiewicz W, Kumar P, Béguelin W, Fontán L, Rivas MA, Pawlikowska P, Armand M, Mouly E et al..  2018.  TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis.. Cancer Discov. 8(12):1632-1653.
Dominguez PM, Ghamlouch H, Rosikiewicz W, Kumar P, Béguelin W, Fontán L, Rivas MA, Pawlikowska P, Armand M, Mouly E et al..  2018.  TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis.. Cancer Discov. 8(12):1632-1653.
2019
Conteduca V, Oromendia C, Eng KW, Bareja R, Sigouros M, Molina A, Faltas BM, Sboner A, Mosquera JMiguel, Elemento O et al..  2019.  Clinical features of neuroendocrine prostate cancer.. Eur J Cancer. 121:7-18.
Khosravi P, Kazemi E, Zhan Q, Malmsten JE, Toschi M, Zisimopoulos P, Sigaras A, Lavery S, Cooper LAD, Hickman C et al..  2019.  Deep learning enables robust assessment and selection of human blastocysts after in vitro fertilization.. NPJ Digit Med. 2:21.
Courtiol P, Maussion C, Moarii M, Pronier E, Pilcer S, Sefta M, Manceron P, Toldo S, Zaslavskiy M, Le Stang N et al..  2019.  Deep learning-based classification of mesothelioma improves prediction of patient outcome.. Nat Med. 25(10):1519-1525.
Puca L, Gavyert K, Sailer V, Conteduca V, Dardenne E, Sigouros M, Isse K, Kearney M, Vosoughi A, Fernandez L et al..  2019.  Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer.. Sci Transl Med. 11(484)
Rai R, Yadav SS, Pan H, Khan I, O'Connor J, Alshalalfa M, Davicioni E, Taioli E, Elemento O, Tewari AK et al..  2019.  Epigenetic analysis identifies factors driving racial disparity in prostate cancer.. Cancer Rep (Hoboken). 2(2):e1153.
Rai R, Yadav SS, Pan H, Khan I, O'Connor J, Alshalalfa M, Davicioni E, Taioli E, Elemento O, Tewari AK et al..  2019.  Epigenetic analysis identifies factors driving racial disparity in prostate cancer.. Cancer Rep (Hoboken). 2(2):e1153.
Ma J, Redmond D, Miyaguchi A, Nam AS, Nie K, Mathew S, Elemento O, Tam W.  2019.  Exploring tumor clonal evolution in bone marrow of patients with diffuse large B-cell lymphoma by deep IGH sequencing and its potential relevance in relapse.. Blood Cancer J. 9(9):69.
Choi S, Wang D, Chen X, Tang LH, Verma A, Chen Z, Kim BJung, Selesner L, Robzyk K, Zhang G et al..  2019.  Function and clinical relevance of RHAMM isoforms in pancreatic tumor progression.. Mol Cancer. 18(1):92.
Sailer V, Eng KWa, Zhang T, Bareja R, Pisapia DJ, Sigaras A, Bhinder B, Romanel A, Wilkes D, Sticca E et al..  2019.  Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.. JCO Precis Oncol. 3
Karass M, Bareja R, Shelkey E, Vlachostergios PJ, Robinson BD, Khani F, Mosquera JMiguel, Scherr DS, Sboner A, Tagawa ST et al..  2019.  Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer.. J Natl Compr Canc Netw. 17(3):194-200.